Stock Details
GILD is Gilead Sciences, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 63.20$. Average daily volumn in 3 months 6.69M. Market cap 78.79B



Stock symbol : GILD. Exchange : NasdaqGS. Currency : USD
Lastest price : 62.86$. Total volume : 7.60M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Gilead Sciences, Inc. (GILD)
Last Price
62.86$
Change
-0.91
Volume
7.60M

Previous Close63.77
Open63.49
Day Range62.30-63.78
Bid62.94 x 1.3k
Ask63.10 x 1.3k
Volume7.6M
Average Volume6.69M
Market Cap78.79B
Beta0.33
52 Week Range57.17-74.12
Trailing P/E19.22
Foward P/E9.72
Dividend (Yield %)4.65%
Ex-Dividend Date2022-09-14



Financial Details


According to Gilead Sciences, Inc.'s financial reports the company's revenue in 2021 were 27.3B an increase( +12.5%) over the years 2020 revenue that were of 24.69B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 123M( +4778.05%).


Loading ...



Organization

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of li... ver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market Cap:
78.79B
Revenue:
27.3B
Total Assets:
67.95B
Total Cash:
5.34B


News about "Gilead Sciences, Inc."

institutional-owners-may-take-dramatic-actions-as-gilead-sciences-incs-nasdaqgild-recent-42-drop-adds-to-one-year-losses-image

Institutional owners may take dramatic actions as Gilead Sciences, Inc.'s (NASDAQ:GILD) recent 4.2% drop adds to one-year losses

Source from : YAHOO!Finance - 1 days ago

A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. We ...See details»


gilead-sciences-inc-nasdaqgild-shares-sold-by-orion-portfolio-solutions-llc-image

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Orion Portfolio Solutions LLC

Source from : Defense World - 20 hours ago

Orion Portfolio Solutions LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 2.8% in the second quarter, according to the company in its most recent 13F filing with the ...See details»


private-advisor-group-llc-buys-2974-shares-of-gilead-sciences-inc-nasdaqgild-image

Private Advisor Group LLC Buys 2,974 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Source from : Defense World - 19 hours ago

Private Advisor Group LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 3.8% in the second quarter, Holdings Channel reports. The firm owned 80,395 shares of the ...See details»


Gilead Sciences, Inc.'s (NASDAQ:GILD) latest 3.2% decline adds to one-year losses, institutional investors may consider drastic measures

Source from : Yahoo - 5 days ago

If you want to know who really controls Gilead Sciences, Inc. (NASDAQ:GILD), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the ...See details»


Gilead settles patent fight with generic drugmakers over HIV drugs

Source from : Reuters - 13 days ago

(Reuters) - Gilead Sciences Inc has settled patent disputes with five drugmakers over proposed generic versions of its blockbuster HIV drugs Descovy and Odefsey and hepatitis B drug Vemlidy ...See details»


Gilead Sciences Completes Acquisition of MiroBio

Source from : Yahoo - 5 days ago

FOSTER CITY, Calif., September 20, 2022--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio ...See details»


Gilead's Trodelvy extends breast cancer survival by 3.2 months -study

Source from : The Jerusalem Post Blogs - 2 days ago

Gilead Sciences Inc's Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a ...See details»


My Biggest Worry About Gilead Sciences

Source from : The Motley Fool - 11 days ago

The Motley Fool has positions in and recommends Gilead Sciences and Merck & Co. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.See details»


Gilead Sciences, Inc. (GILD) Presents at Baird 2022 Global Healthcare Conference (Transcript)

Source from : Seeking Alpha - 11 days ago

Baird 2022 Global Healthcare Conference September 14, 2022 09:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer ...See details»


Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

Source from : Seeking Alpha - 12 days ago

I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Gilead with us here. We have Dan O'Day, who's the CEO; and Bill Grossman, who heads up oncology.See details»


Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players

Source from : MSN - 12 days ago

Shares of Gilead Sciences, Inc. GILD gained 4.2% after management announced agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with some of GILD ...See details»


Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines

Source from : Daily Herald - 3 days ago

Public-Private Effort to Shift Traditional Model of Hepatitis Management to Primary Care and Help to Expand Care to More People in Need - Gilead Sciences, Inc. today announced a new public-private ...See details»


Gilead Sciences Gets CHMP Backing for Expanded Yescarta Use >GILD

Source from : MarketWatch - 9 days ago

By Colin Kellaher Gilead Sciences Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended ...See details»


Gilead Sciences Completes Acquisition of MiroBio

Source from : PharmiWeb - 3 days ago

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based ...See details»